These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 7630145)
1. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation. Darpö B; Almgren O; Bergstrand R; Bäärnhielm C; Gottfridsson C; Sandstedt B; Edvardsson N J Cardiovasc Pharmacol; 1995 May; 25(5):681-90. PubMed ID: 7630145 [TBL] [Abstract][Full Text] [Related]
2. Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings. Darpö B; Vallin H; Almgren O; Bergstrand R; Insulander P; Edvardsson N J Cardiovasc Pharmacol; 1995 Oct; 26(4):530-40. PubMed ID: 8569212 [TBL] [Abstract][Full Text] [Related]
3. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. Wiesfeld AC; De Langen CD; Crijns HJ; Bel KJ; Hillege HL; Wesseling H; Lie KI J Cardiovasc Pharmacol; 1996 Apr; 27(4):594-600. PubMed ID: 8847879 [TBL] [Abstract][Full Text] [Related]
4. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Wiesfeld AC; Crijns HJ; Tobé TJ; Almgren O; Bergstrand RH; Aberg J; Haaksma J; Lie KI Am J Cardiol; 1992 Oct; 70(11):990-6. PubMed ID: 1384304 [TBL] [Abstract][Full Text] [Related]
5. Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals. Darpö B; Almgren O; Bergstrand R; Franzén S; Edvardsson N Cardiovasc Drugs Ther; 1996 Nov; 10(5):539-47. PubMed ID: 8950068 [TBL] [Abstract][Full Text] [Related]
6. Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group. Darpö B; Edvardsson N Cardiovasc Drugs Ther; 1997 Jul; 11(3):499-508. PubMed ID: 9310280 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog. Duker G; Almgren O; Carlsson L J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293 [TBL] [Abstract][Full Text] [Related]
8. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747 [TBL] [Abstract][Full Text] [Related]
9. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913 [TBL] [Abstract][Full Text] [Related]
10. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. Darpö B; Edvardsson N J Cardiovasc Pharmacol; 1995 Aug; 26(2):198-206. PubMed ID: 7475043 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects of E 4031, a drug with selective class III properties, in man. Katritsis D; Morgan J; Brachmann J; Bygrave A; O'Farrell D; Rowland E; Camm AJ Pacing Clin Electrophysiol; 1997 Apr; 20(4 Pt 1):930-7. PubMed ID: 9127398 [TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of Org 7797 in the closed-chest anaesthetized dog. Leboeuf J; Basiez M; Massingham R Br J Pharmacol; 1993 Sep; 110(1):23-8. PubMed ID: 8220882 [TBL] [Abstract][Full Text] [Related]
13. QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agent. Houltz B; Darpö B; Crijns HJ; Swedberg K; Blomström P; Jensen SM; Svernhage E; Edvardsson N J Electrocardiol; 2002 Jul; 35(3):201-12. PubMed ID: 12122610 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiological effects of a new antiarrhythmic agent, nicainoprol, in humans. Sen S; Rettig G; Ozbek C; Fröhlig G; Schieffer H; Bette L J Cardiovasc Pharmacol; 1986; 8(1):144-50. PubMed ID: 2419677 [TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of sinus node, atrioventricular node, atrium, and ventricle to propranolol. Chang MS; Zipes DP Am Heart J; 1988 Aug; 116(2 Pt 1):371-8. PubMed ID: 3400563 [TBL] [Abstract][Full Text] [Related]
16. Canine electrophysiology of encainide, a new antiarrhythmic drug. Sami M; Mason JW; Oh G; Harrison DC Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174 [TBL] [Abstract][Full Text] [Related]
17. Potent and reversible effects of ATI-2001 on atrial and atrioventricular nodal electrophysiological properties in guinea pig isolated perfused heart. Raatikainen MJ; Morey TE; Druzgala P; Milner P; Gonzalez MD; Dennis DM J Pharmacol Exp Ther; 2000 Nov; 295(2):779-85. PubMed ID: 11046118 [TBL] [Abstract][Full Text] [Related]
18. Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart. Bińkowski BJ; Makowski M; Kubiński P; Lubiński A Cardiovasc Drugs Ther; 2018 Apr; 32(2):169-173. PubMed ID: 29623481 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Wettwer E; Grundke M; Ravens U Cardiovasc Res; 1992 Nov; 26(11):1145-52. PubMed ID: 1291093 [TBL] [Abstract][Full Text] [Related]
20. Atrial, SA nodal, and AV nodal electrophysiology in standing horses: normal findings and electrophysiologic effects of quinidine and diltiazem. Schwarzwald CC; Hamlin RL; Bonagura JD; Nishijima Y; Meadows C; Carnes CA J Vet Intern Med; 2007; 21(1):166-75. PubMed ID: 17338165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]